Skip to main
STIM

Neuronetics Inc (STIM) Stock Forecast & Price Target

Neuronetics Inc (STIM) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Neuronetics is a strong and growing company with a unique product in the current mental health market. With its NeuroStar Advance Therapy System, the company offers a non-invasive alternative for treating depression and has a well-developed commercial model to reach a larger customer base. The company is also well-positioned for future growth with its collaboration with Compass Pathways for psilocybin therapy and its recent integration with AdvancedMD for improved revenue cycle management. The company has shown positive financial results with increased revenue and gross margin and a move towards sustained profitability.

Bears say

Neuronetics is facing numerous unknowns in the emerging field of interventional psychiatry, specifically with the anticipated commercial launch of COMP360, a psilocybin therapy. While the company has some competitive advantages in this space, such as an existing collaboration with COMPASS, operational infrastructure, and available capacity, it is still unclear how the opportunity for this type of therapy will play out in terms of FDA approval, reimbursement, and utilization among patients and physicians. Additionally, the company's traditional NeuroStar treatment model is facing challenges and transition as they incorporate a new go-to-market strategy.

Neuronetics Inc (STIM) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Neuronetics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Neuronetics Inc (STIM) Forecast

Analysts have given Neuronetics Inc (STIM) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Neuronetics Inc (STIM) has a Strong Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Neuronetics Inc (STIM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.